Researchers from the University of Colorado and Tel Aviv University have reported a case study that suggests fluorescence in situ hybridization-based testing may miss some ALK rearrangements in lung cancer patients who could benefit from Pfizer's Xalkori (crizotinib).
Clinical Care Options, a developer of continuing education and medical decision support resources, has launched a web-based tool to help oncologists figure out which lung cancer patients may benefit from molecularly guided personalized treatments.
Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlo
NEW YORK (GenomeWeb News) – Transgenomic said today that it is collaborating with New York University Langone Medical Center to use its Ice-Cold-PCR technology to study the molecular basis of non-small cell lung cancer and therapeutic response to existing and novel NSCLC therapies.
NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.